Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Enjoy A nurse will come to you, so you can enjoy your treatment wherever you are
Starting or intensifying resistance training during treatment may temporarily slow weight loss as you build muscle, which is denser than fat
Why This Three-Entity Structure Matters This separation is legally required to ensure that: Platform companies don't practice medicine without a license - Technology platforms cannot make clinical decisions Clinical independence is preserved - Prescribers must make medical judgments free from commercial pressure Pharmacy regulations are followed - Medication dispensing must comply with state and federal pharmacy laws For you as a patient, this means: You're not getting medical care "from Elevate Health" - you're getting it from independent providers who use Elevate Health's platform The platform coordinates the process but doesn't control whether you get a prescription If there's a clinical question or medication issue, you'll interact with the provider or pharmacy, not just the platform's customer service team This three-entity structure is common across telehealth platforms and ensures appropriate separation between the technology platform, clinical decision-making, and medication dispensing
In addition, any arginine not converted to urea enters general circulation where it is distributed to various tissues and metabolized for other uses such as protein synthesis
peaks during dose escalation, typically mild-moderate Diarrhea -- 10-20%, usually transient Constipation -- 8-15% Vomiting -- 5-15%, more frequent at higher doses Injection site reactions -- 5-10%, mild erythema and pruritus Decreased appetite -- 5-12%, related to mechanism of action Pancreatitis -- rare but monitored (as with all GLP-1/amylin agents) Gallbladder events -- cholelithiasis reported, consistent with rapid weight loss Trial data describes dose titration as central to tolerability -- the 16-week escalation protocol substantially reduced GI adverse events
